The FDA has posted a summary of Novo Nordisk (NVO) site inspections made over several dates in March of this year at the company’s Drug Substance Manufacturing Site in Kalundborg Sjalland 4400 DK.

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up. Less than a ...

(Bloomberg) -- Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up.

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuster glucagon-like ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

Economic data in Q3 indicated lower inflation and employment, prompting the Fed to cut interest rates by 50bps, influencing global markets and sector performance. Our portfolio underperformed the ...

Shares in Novo Nordisk A/S (DK:NOVO.B) have lost a fifth of their market value since the end of June, the point at which the Danish pharma group revealed that it was committing around $4bn (£3.2bn) to ...